国际肾病研究院研究表明：健帆的血液灌流器具有绝对优良的安全性
发布时间：2018-01-22
导读
最新一期的“Ronco 教授卡布奇诺漫谈”中，意大利San Bortolo医院国际肾脏病研究所、ADQI创立主席Claudio Ronco教授介绍了与健帆的合作。国际肾病研究院（IRRIV）刚刚结束的体外研究表明健帆的血液灌流器具有绝对优良的安全性。实验结果将在近期发表，同时针对不同适应症的临床测试也在正在筹划中。
Ronco教授提到：
We were pleased to display the recent result of our institute on the cartridge for adsorption used in hemoperfusion from Jafron company. I think the interesting results that we got where that the safety issue is now completely clarified because we tested in vitro both static and dynamic situation, with three different cartridges (HA130, HA230 and HA330/HA380) for adsorption and there is no activation at all of any of the products that may activate monocyte cells in vitro. This test is even more sensitive compare to any type of molecular analysis because the cellular response is so sensitive in terms of apotosis and necrosis that can detect even very very neglectable and minimun of components for various compatibility…So at this point we are ready to publish this results and once we published the result we are ready now to move for in vivo evaluation of different cartridges for diffrent options including removal of cytokines, removal of endotoxin, possible removal of products bound protein in case of liver failure and also we want to analyse the compacity of these adsorbent for important substances…I think this is the step forward that we always talk about sorbents is the future!
很高兴在此展示最近我们研究所得出的关于健帆公司血液灌流器的研究成果。我认为健帆灌流器的安全性通过采用静态和动态两种测试方法，已经彻底得到验证。我们检测了三种型号的血液灌流器(HA130, HA230 和 HA330)，任一产品对单核细胞都没有任何活化作用。与其他类型的分子分析相比，这种测试具有更高的灵敏度，因为对凋亡和坏死的细胞应答检测是如此敏感，以至于十分微小甚至很容易忽略的不同兼容性的成份都能被察觉……最近我们将公布测试结果，在发布体外测试的结果后，我们会着手不同型号的血液灌流器的各种临床测试，如探索去除炎症因子、内毒素，在肝衰情况下去除蛋白结合类物质的可能等。并且我们也会分析这些吸附剂与体内重要物质的相容性……我觉得，这次研究测试向我们常说的 ‘吸附就是未来’迈进了一大步！
导读
最新一期的“Ronco 教授卡布奇诺漫谈”中，意大利San Bortolo医院国际肾脏病研究所、ADQI创立主席Claudio Ronco教授介绍了与健帆的合作。国际肾病研究院（IRRIV）刚刚结束的体外研究表明健帆的血液灌流器具有绝对优良的安全性。实验结果将在近期发表，同时针对不同适应症的临床测试也在正在筹划中。
Ronco教授提到：
We were pleased to display the recent result of our institute on the cartridge for adsorption used in hemoperfusion from Jafron company. I think the interesting results that we got where that the safety issue is now completely clarified because we tested in vitro both static and dynamic situation, with three different cartridges (HA130, HA230 and HA330/HA380) for adsorption and there is no activation at all of any of the products that may activate monocyte cells in vitro. This test is even more sensitive compare to any type of molecular analysis because the cellular response is so sensitive in terms of apotosis and necrosis that can detect even very very neglectable and minimun of components for various compatibility…So at this point we are ready to publish this results and once we published the result we are ready now to move for in vivo evaluation of different cartridges for diffrent options including removal of cytokines, removal of endotoxin, possible removal of products bound protein in case of liver failure and also we want to analyse the compacity of these adsorbent for important substances…I think this is the step forward that we always talk about sorbents is the future!
很高兴在此展示最近我们研究所得出的关于健帆公司血液灌流器的研究成果。我认为健帆灌流器的安全性通过采用静态和动态两种测试方法，已经彻底得到验证。我们检测了三种型号的血液灌流器(HA130, HA230 和 HA330)，任一产品对单核细胞都没有任何活化作用。与其他类型的分子分析相比，这种测试具有更高的灵敏度，因为对凋亡和坏死的细胞应答检测是如此敏感，以至于十分微小甚至很容易忽略的不同兼容性的成份都能被察觉……最近我们将公布测试结果，在发布体外测试的结果后，我们会着手不同型号的血液灌流器的各种临床测试，如探索去除炎症因子、内毒素，在肝衰情况下去除蛋白结合类物质的可能等。并且我们也会分析这些吸附剂与体内重要物质的相容性……我觉得，这次研究测试向我们常说的 ‘吸附就是未来’迈进了一大步！
